FCF Grants Awarded to Dialectic Therapeutics
Total grants: 1
- DT2216 in Combination with Irinotecan: A Phase 1 Study with a Phase 2 Feasibility Cohort for Fibrolamellar Carcinoma — Principal investigator(s): Allison O'Neill, Michael Ortiz — 2025
This list represents the complete set of Fibrolamellar Cancer Foundation grants awarded to Dialectic Therapeutics.